局部晚期非小细胞肺癌:当前问题和最近的趋势
1Comprehensive Cancer Centre, Radiation Oncology, King Fahad Medical City, Riyadh, Kingdom of Saudi Arabia.
概括
本综述讨论了局部晚期非小细胞肺癌 (LA NSCLC) 治疗趋势. 同时进行化学放射治疗,然后服用杜尔瓦卢马布是当前的标准,改善了LA NSCLC患者的治疗结果.
科学领域:
- 在瘤学瘤学.
- 辐射瘤学 辐射瘤学
- 医疗成像医学成像
背景情况:
- 局部晚期 (LA) 非小细胞肺癌 (NSCLC) 提出了复杂的治疗挑战.
- 第8版的瘤结节转移 (TNM) 阶段系统已经引入了影响LA NSCLC分类和结果的修订.
- 目前LA NSCLC的治疗模式包括化疗放射治疗,先进技术和免疫治疗的作用在不断变化.
研究的目的:
- 审查和总结当前的问题和最近的趋势,在当地先进的非小细胞肺癌的管理.
- 评估第八个TNM分阶段系统对LA NSCLC分层和结果的影响.
- 讨论放射治疗技术的进步和免疫治疗在LA NSCLC中新兴的作用.
主要方法:
- 文献综述和对LA NSCLC当前研究的综合.
- 对TNM分期系统进行比较的研究分析 (第7版与第8版).
- 对化学放射治疗,先进的放射治疗技术 (4D-CT,VMAT) 和免疫治疗 (杜尔瓦卢马布) 的临床试验数据的审查.
主要成果:
- 与LA NSCLC的第7版相比,第8版TNM在改善歧视和临床结果方面显示出混合的结果.
- 与照射疗法相比,同时进行放射化疗可以降低局部复发和远程转移的风险,但仍然存在毒性问题.
- 该PACIFIC试验确立了并发化疗放射治疗,其次是杜瓦卢马布作为不可手术的LA NSCLC的标准护理,证明了显著的长期生存益处.
结论:
- 尽管有4D-CT和VMAT等进展,但LA NSCLC的最佳放射治疗技术仍在争论中.
- 免疫疗法,特别是化学放射治疗后的杜尔瓦卢马布维护,代表了LA NSCLC治疗的重大进展.
- 随着LA NSCLC管理的不断变化,需要对最佳分期,治疗方式和新的治疗组合进行持续的研究.
关键词:
同时进行放射化疗.免疫检查点抑制剂 免疫检查点抑制剂免疫疗法 免疫疗法局部先进的非小细胞肺癌.被动散射质子疗法是一种被动散射质子疗法.质子疗法是一种质子疗法.辐射疗法 辐射疗法顺序性的放射化疗疗法.瘤结节转移的发生.容量调节弧线疗法是指体积调节的弧线疗法.更多相关视频
10:29Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
Published on: August 14, 2019
10.6K
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
10.5K
相关概念视频
02:57Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
02:49Cancer Therapies
7.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.7K
02:39lncRNA - Long Non-coding RNAs
8.7K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.7K